🔎 Trials Near Me

ホーム › 頭頸部扁平上皮癌 › ノースカロライナ

ノースカロライナにおける頭頸部扁平上皮癌の臨床試験

ノースカロライナ内の拠点で、頭頸部扁平上皮癌に関する27件の研究が参加者を募集しています。

ノースカロライナ内の都市

公式研究テキスト(英語)

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  • Site#0118, Durham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06788990

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #12, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Margaret R Pardee Memorial Hospital, Hendersonville
  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06589804

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  • Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07360314

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  • Carolina Cancer Research Center, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07276399

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  • University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06385080

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • Southeastern Medical Oncology Center-Jacksonville, Jacksonville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health Levine Cancer Institute, Charlotte
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT04892173

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  • University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/25更新 · NCT07219212

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Cone Health Cancer Center, Greensboro
  • Annie Penn Memorial Hospital, Reidsville
被験者募集中第2相
18歳〜79歳 · 全性別 · 2026/09/22更新 · NCT04671667

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Carolina Biooncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • UNC- Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT02734537

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04333537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  • Atrium Health Stanly/LCI-Albemarle, Albemarle
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Pineville/LCI-Pineville, Charlotte
  • 他9件
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06532279

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/17更新 · NCT04375384

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • Carolina BioOncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

  • Duke Cancer Center /ID# 251975, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04777994

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

  • University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/04/28更新 · NCT04564989

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Carolina BioOncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Duke Cancer Institute, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Huntersville
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

  • Duke University Medical Center, Durham
被験者募集中
18歳以上 · 全性別 · 2025/12/11更新 · NCT05793151

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of North Carolina, Chapel Hill
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Levine Cancer Institute, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2025/08/15更新 · NCT04429542

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。